Menkes Disease Clinical Trials and Treatments

Menkes disease results from mutations in the ATP7A gene on the X chromosome, which encodes a P-type ATPase responsible for transporting copper across cell membranes and into the secretory pathway. Copper is a cofactor for critical enzymes including cytochrome c oxidase (mitochondrial energy production), lysyl oxidase (connective tissue crosslinking), dopamine beta-hydroxylase (catecholamine synthesis), and tyrosinase (melanin production). When ATP7A is dysfunctional, dietary copper is absorbed into intestinal cells but cannot be exported into the bloodstream, creating a paradox of copper excess in some tissues and severe deficiency in others.

The most common symptoms of Menkes Disease include Sparse, kinky, colorless or steel-colored hair (pili torti) that breaks easily, Failure to thrive with poor weight gain and feeding difficulties, Progressive developmental regression and loss of milestones after 2-3 months, Seizures, often intractable, beginning in infancy, Severe hypotonia (floppy muscle tone), among others. Menkes Disease affects approximately 1 in 35,000 to 100,000 live male births in the U.S. Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Menkes Disease from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. The approval of copper histidinate (Zycubo) in January 2026 represents a landmark for Menkes disease, but timing is everything. Research consistently shows that treatment initiated before 4 weeks of age, ideally within days of birth, produces the best neurological outcomes.

Yes. As of October 21, 2026, 1 FDA-approved medicine has a current label that names Menkes Disease: Zycubo (copper histidinate), first approved in 2026. Corticosteroids and immune globulins count once each.

Menkes Disease is caused by variants in the ATP7A gene. About one-third of cases are de novo ATP7A variants.

It is X-linked, so it mainly affects boys, and a mother who carries the variant has a 1 in 2 chance of passing it to each son. The condition affects approximately 1 in 35,000 to 100,000 live male births in the U.S. Genetic testing confirms the diagnosis.

Yes. Genetic testing for Menkes Disease looks at the ATP7A gene. About one-third of cases are de novo ATP7A variants.

It is X-linked, so it mainly affects boys, and a mother who carries the variant has a 1 in 2 chance of passing it to each son.

A confirmed variant establishes the diagnosis and is often required to enroll in gene-specific trials. The labs currently offering the test are listed in the Genetic Testing section of this page, pulled live from the NIH Genetic Testing Registry. A genetic counselor can help interpret the result and decide which relatives should be tested.

Eligibility for Menkes Disease clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Menkes Disease clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.